ibrutinib
Ibrutinib is used to treat chronic lymphocytic leukemia Waldenström's macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, marginal zone lymphoma, and chronic graft vs host disease. It is a small molecule drug. Reference standards of Ibrutinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object
(
[pname] => (R)-1-Boc-3-Hydroxypiperidine (BSC)
[catalogue_number] => PA BSC 02709853
[category_ids] => ,169,
[chemical_name] =>
[weight] => 201.27
[form] => C10H19NO3
[cas] => 143900-43-0
[pslug] => 143900-43-0-r-1-boc-3-hydroxypiperidine-bsc-pabsc02709853
[latest_product] => 0
[linkproducts] => 0
[offers_id] =>
[offers_name] =>
[offers_status] =>
[offers_start_date] =>
[offers_end_date] =>
[pageview] =>
[offers_slug] =>
[offers_product_id] =>
[offers_product_code] =>
[offers_master_id] =>
[offer_percentage] =>
[offers_product_main_cat] =>
)
(R)-1-Boc-3-Hydroxypiperidine (BSC)
Catalogue No.:PA BSC 02709853
Molecular Formula : C10H19NO3
Molecular Weight : 201.27